Global Artificial Blood Vessels Market Forecast 2024-2032

The global artificial blood vessels market size was $3588.59 million in 2023 and is expected to reach $6140.48 million by 2032, growing at a CAGR of 6.04% during the forecast period from 2024 to 2032.

The global artificial blood vessels market is driven by factors such as the high prevalence of cardiovascular diseases and significant advancements in blood vessel replacement materials. The demand for synthetic artificial blood vessels is particularly pronounced in surgeries addressing conditions like coronary artery disease and peripheral artery disease. Technological innovations, such as 3D printing for creating artificial blood vessels, have revolutionized the industry by offering customized solutions and enhancing surgical outcomes.

The development of advanced materials has improved the durability and biocompatibility of artificial blood vessels, effectively meeting the diverse needs of patients. Furthermore, the rising aging population, which is more susceptible to cardiovascular ailments, is a key factor driving the demand for artificial blood vessels and necessitating frequent surgical interventions. These trends indicate a steady growth trajectory for the global artificial blood vessels market, with opportunities for further innovation and market penetration in minimally invasive surgical techniques and artificial blood for transfusion.

MARKET INSIGHTS

Key growth enablers of the global artificial blood vessels market:

Rising prevalence of cardiovascular diseases and vascular disorders

The increasing prevalence of cardiovascular diseases (CVDs) globally is driving the demand for artificial blood vessels. CVDs, the leading cause of death worldwide according to the WHO, claim approximately 18.6 million lives annually. In parallel, in the United States, heart disease, the primary contributor to CVD-related deaths, results in over 697,000 fatalities each year and affects around 121.5 million adults. Stroke, another significant vascular disorder, contributes substantially to disability and mortality, with nearly 800,000 cases reported annually.

The economic burden of CVDs surpasses $1 trillion annually, substantially affecting global productivity. Consequently, there is an urgent need for innovative treatments. Artificial blood vessels, crucial in surgical procedures such as coronary artery bypass grafting and peripheral artery bypasses, are vital in restoring blood flow and improving patient outcomes, effectively addressing the challenges posed by CVDs and other vascular disorders.

Advancements in tissue engineering and regenerative medicine
Growing geriatric population and changing lifestyles

Key growth restraining factors of the global artificial blood vessels market:

High costs associated with the development and commercialization of artificial blood vessels
Stringent regulatory approvals and clinical trial requirements

Stringent regulatory approvals and extensive clinical trial requirements present considerable challenges for the global artificial blood vessels market. These requirements, mandated by regulatory bodies like the FDA in the United States and similar authorities worldwide, are crucial for ensuring the safety and efficacy of medical devices. However, they result in prolonged approval timelines and increased costs for manufacturers.

Compliance with high-risk classification standards adds additional complexity, requiring extensive preclinical and clinical data reviews. The rigorous criteria for clinical trials, which span multiple phases and demand substantial financial investment and specialized expertise, create barriers to market entry and product commercialization.

Moreover, the introduction of stricter regulations, such as the European Union Medical Device Regulation, exacerbates these challenges, increasing the complexity of the approval process.

Concerns regarding biocompatibility and long-term durability

Global Artificial Blood Vessels Market | Top Market Trends

A notable trend in the global artificial blood vessels market is the increasing utilization of 3D bioprinting techniques. Traditional artificial blood vessels often rely on synthetic materials or cadaveric vessels, which may have limited durability and pose risks of complications. However, 3D bioprinting offers an innovative approach by enabling the creation of patient-specific, biocompatible vascular grafts. For instance, researchers at the University of Minnesota have achieved a significant milestone by bioprinting a life-sized model of a patient's cardiovascular system. Therefore, this breakthrough paves the way for producing customized vascular grafts that closely mimic the properties and structures of natural blood vessels. Advancements in 3D bioprinting hold immense potential for improving the efficacy and safety of artificial blood vessel implants, thereby transforming treatment paradigms for cardiovascular diseases.
Another key trend in the global artificial blood vessels market is the increasing incorporation of nanotechnology and biomimetic materials. Nanotechnology, which involves manipulating materials at the nanoscale, offers unique opportunities to enhance the properties and performance of artificial blood substitutes. Additionally, biomimetic materials, designed to mimic the structure and function of natural biological systems, provide a more compatible and effective alternative to traditional synthetic materials. This trend underscores a growing emphasis on leveraging advanced scientific principles to develop artificial blood vessels with improved biocompatibility, durability, and performance, thereby enhancing patient outcomes and expanding the scope of treatment options for cardiovascular diseases.

SEGMENTATION ANALYSIS

Market Segmentation - Type, Blood Vessel Diameter, Patient Demographics, Application, and End-User -

Market by Type:

Expanded Polytetrafluoroethylene (ePTFE)

The expanded polytetrafluoroethylene (ePTFE) segment is estimated to be the fastest-growing type category during the forecast period.

Expanded Polytetrafluoroethylene (ePTFE) is a synthetic fluoropolymer material extensively employed in the production of artificial blood vessels. It features a unique microporous structure characterized by interconnected nodes and fibrils, facilitating tissue ingrowth and enhancing biocompatibility. The microporous nature of ePTFE enables it to mimic the properties of natural blood vessels, promoting adequate blood flow and minimizing the risk of thrombosis or occlusion.

ePTFE exhibits exceptional chemical resistance, making it inert to bodily fluids and substances, thereby enhancing its durability for long-term implantation. Additionally, this material demonstrates high tensile strength and flexibility, allowing it to withstand the pressure and pulsatile flow within the cardiovascular system.

Manufacturers utilize techniques such as stretching, sintering, and surface modifications to enhance the surface characteristics of ePTFE grafts. These processes aim to optimize cellular adhesion, endothelialization, and integration within the body, ultimately improving the performance and longevity of the implanted grafts.

While ePTFE is widely used in vascular surgery, particularly for bypass procedures and arteriovenous access for hemodialysis, ongoing research is focused on potential modifications to further enhance its efficacy. Strategies include incorporating bioactive molecules, altering surface topography, or combining ePTFE with other materials to improve properties such as antithrombogenicity and cellular compatibility.

Polyethylene Terephthalate (PET)
Polyurethane
Other Types

Market by Blood Vessel Diameter:

Large

Large artificial blood vessel grafts typically have a diameter ranging from 6 mm to 30 mm or larger, designed to replace or bypass major blood vessels like the aorta, iliac arteries, or femoral arteries.

Further, these grafts are engineered to endure the high pressures and flow rates of the cardiovascular system's major blood vessels. Large artificial blood vessel grafts are commonly used in procedures such as aortic aneurysm repair, where a section of the aorta, the body's main artery, is replaced with a synthetic graft. The selection of the appropriate graft material and design for large blood vessel applications depends on various factors, including the specific location and diameter of the vessel being replaced, the anticipated blood flow rates and pressures, and the patient's characteristics.

Looking ahead, manufacturers use various techniques to optimize the performance of large artificial blood vessel grafts. These techniques may include incorporating reinforcement layers or rings to maintain patency and prevent kinking or collapsing, as well as surface modifications to enhance biocompatibility and reduce the risk of thrombosis or infections. Large artificial blood vessel grafts are typically employed in open surgical procedures, where the graft is sutured or anastomosed to the existing blood vessels.

Medium
Small

Market by Patient Demographics:

Pediatric
Adult

Market by Application:

Peripheral Artery
Hemodialysis
Aortic Disease

Market by End-User:

Hospital
Specialty Clinic
Ambulatory Surgical Center
Other End-Users

REGIONAL ANALYSIS

Geographical Study based on Four Major Regions:

North America: The United States and Canada
Europe: The United Kingdom, Germany, France, Italy, Spain, Switzerland, Poland, and Rest of Europe
Asia-Pacific: China, Japan, India, South Korea, Indonesia, Thailand, Vietnam, Australia & New Zealand, and Rest of Asia-Pacific

The Asia-Pacific is anticipated to be the leading region over the forecasted years.

The Asia-Pacific has witnessed substantial growth in the global artificial blood vessels market, driven by several key factors. Notably, the increasing prevalence of cardiovascular diseases throughout the region has heightened the demand for vascular grafts and related medical procedures.

The aging populations in countries such as Japan and China have further fueled market growth, as elderly individuals are more prone to conditions that necessitate vascular interventions.

Moreover, the enhancement of healthcare infrastructure and rising healthcare expenditures in developing nations across the Asia-Pacific have improved access to advanced medical treatments, including vascular surgeries.

In focus, key players in the market, including Terumo Corporation and W L Gore & Associates Inc, have leveraged these favorable conditions to further propel the market's growth.

Rest of World: Latin America, the Middle East & Africa

COMPETITIVE INSIGHTS

Major players in the global artificial blood vessels market:

B Braun Melsungen AG
Becton Dickinson and Company
LeMaitre Vascular INC
Medtronic plc
Terumo Medical Corporation

Key strategies adopted by some of these companies:

Getinge acquired Applikon Biotechnology in January 2020. Applikon specializes in the development and supply of advanced bioreactor systems for the research and production of vaccines and antibodies in the biopharmaceutical industry, as well as enzymes and bio-plastics for industrial biotechnology.
Becton Dickinson and Company acquired Venclose Inc on December 2, 2021, thereby expanding its portfolio to include solutions for chronic venous insufficiency (CVI) treatment. Venclose's innovative Radio Frequency (RF) ablation technology platform addresses a significant therapeutic need, affecting up to 40% of women and 17% of men in the United States.
W L Gore & Associates announced a collaboration with Arzeda, a Protein Design Company(TM), on June 27, 2022. This partnership focuses on leveraging Arzeda's technology platform to efficiently create and enhance proteins. With increasing demand for innovative and sustainably produced materials, both companies aim to meet consumer needs for performance and sustainability. By optimizing bio-based and biodegradable proteins, the collaboration seeks to improve material performance while minimizing waste and resource intensity in manufacturing processes.

We Offer 10% Free Customization and 3 Months Analyst Support

Frequently Asked Questions (FAQs):

Are artificial blood vessels compatible with the human body?

A: Yes, artificial blood vessels are engineered to be biocompatible, ensuring they are compatible with the human body and do not cause adverse reactions or immune responses.

Can artificial blood vessels be customized for individual patients?

A: Yes, technological advancements enable the customization of artificial blood vessels to meet the specific size and shape requirements of individual patients.

How are artificial blood vessels sterilized before implantation?

A: Artificial blood vessels undergo stringent sterilization processes to ensure they are free from contaminants and pathogens, commonly using methods such as gamma irradiation or ethylene oxide sterilization.

Product Code: 91484

1. RESEARCH SCOPE & METHODOLOGY

1.1. STUDY OBJECTIVES
1.2. METHODOLOGY
1.3. ASSUMPTIONS & LIMITATIONS

2. EXECUTIVE SUMMARY

2.1. MARKET SIZE & ESTIMATES
2.2. MARKET OVERVIEW
2.3. SCOPE OF STUDY
2.4. CRISIS SCENARIO ANALYSIS
- 2.4.1. IMPACT OF COVID-19 ON THE GLOBAL ARTIFICIAL BLOOD VESSELS MARKET
2.5. MAJOR MARKET FINDINGS
- 2.5.1. AORTIC DISEASES INCREASE IS SEEN AS A CATALYST FOR MARKET GROWTH

3. MARKET DYNAMICS

3.1. KEY DRIVERS
- 3.1.1. RISING PREVALENCE OF CARDIOVASCULAR DISEASES AND VASCULAR DISORDERS
- 3.1.2. ADVANCEMENTS IN TISSUE ENGINEERING AND REGENERATIVE MEDICINE
- 3.1.3. GROWING GERIATRIC POPULATION AND CHANGING LIFESTYLES
3.2. KEY RESTRAINTS
- 3.2.1. HIGH COSTS ASSOCIATED WITH THE DEVELOPMENT AND COMMERCIALIZATION OF ARTIFICIAL BLOOD VESSELS
- 3.2.2. STRINGENT REGULATORY APPROVALS AND CLINICAL TRIAL REQUIREMENTS
- 3.2.3. CONCERNS REGARDING BIOCOMPATIBILITY AND LONG-TERM DURABILITY

4. KEY ANALYTICS

4.1. KEY MARKET TRENDS
- 4.1.1. DEVELOPMENT OF 3D BIOPRINTING TECHNIQUES FOR CUSTOMIZED VASCULAR GRAFTS
- 4.1.2. INCORPORATION OF NANOTECHNOLOGY AND BIOMIMETIC MATERIALS FOR IMPROVED FUNCTIONALITY
4.2. PORTER'S FIVE FORCES ANALYSIS
- 4.2.1. BUYERS POWER
- 4.2.2. SUPPLIERS POWER
- 4.2.3. SUBSTITUTION
- 4.2.4. NEW ENTRANTS
- 4.2.5. INDUSTRY RIVALRY
4.3. GROWTH PROSPECT MAPPING
- 4.3.1. GROWTH PROSPECT MAPPING FOR NORTH AMERICA
- 4.3.2. GROWTH PROSPECT MAPPING FOR EUROPE
- 4.3.3. GROWTH PROSPECT MAPPING FOR ASIA-PACIFIC
- 4.3.4. GROWTH PROSPECT MAPPING FOR REST OF WORLD
4.4. MARKET MATURITY ANALYSIS
4.5. MARKET CONCENTRATION ANALYSIS
4.6. VALUE CHAIN ANALYSIS
- 4.6.1. RAW MATERIALS
- 4.6.2. MANUFACTURERS
- 4.6.3. DISTRIBUTORS
- 4.6.4. END-USER
4.7. KEY BUYING CRITERIA
- 4.7.1. BIOCOMPATIBILITY
- 4.7.2. DURABILITY AND LONGEVITY
- 4.7.3. CUSTOMIZATION AND VERSATILITY
- 4.7.4. REGULATORY COMPLIANCE AND QUALITY ASSURANCE

5. MARKET BY TYPE

5.1. EXPANDED POLYTETRAFLUOROETHYLENE (EPTFE)
5.2. POLYETHYLENE TEREPHTHALATE (PET)
5.3. POLYURETHANE
5.4. OTHER TYPES

6. MARKET BY BLOOD VESSEL DIAMETER

6.1. LARGE
6.2. MEDIUM
6.3. SMALL

7. MARKET BY PATIENT DEMOGRAPHICS

7.1. PEDIATRIC
7.2. ADULT

8. MARKET BY APPLICATION

8.1. PERIPHERAL ARTERY
8.2. HEMODIALYSIS
8.3. AORTIC DISEASE

9. MARKET BY END-USER

9.1. HOSPITAL
9.2. SPECIALTY CLINIC
9.3. AMBULATORY SURGICAL CENTER
9.4. OTHER END-USERS

10. GEOGRAPHICAL ANALYSIS

10.1. NORTH AMERICA
- 10.1.1. MARKET SIZE & ESTIMATES
- 10.1.2. NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET DRIVERS
- 10.1.3. NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET CHALLENGES
- 10.1.4. NORTH AMERICA ARTIFICIAL VESSELS MARKET REGULATORY FRAMEWORK
- 10.1.5. KEY PLAYERS IN NORTH AMERICA ARTIFICIAL BLOOD VESSELS MARKET
- 10.1.6. COUNTRY ANALYSIS
  - 10.1.6.1. UNITED STATES
  - 10.1.6.1.1. UNITED STATES ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.1.6.2. CANADA
  - 10.1.6.2.1. CANADA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
10.2. EUROPE
- 10.2.1. MARKET SIZE & ESTIMATES
- 10.2.2. EUROPE ARTIFICIAL BLOOD VESSELS MARKET DRIVERS
- 10.2.3. EUROPE ARTIFICIAL BLOOD VESSELS MARKET CHALLENGES
- 10.2.4. EUROPE ARTIFICIAL VESSELS MARKET REGULATORY FRAMEWORK
- 10.2.5. KEY PLAYERS IN EUROPE ARTIFICIAL BLOOD VESSELS MARKET
- 10.2.6. COUNTRY ANALYSIS
  - 10.2.6.1. UNITED KINGDOM
  - 10.2.6.1.1. UNITED KINGDOM ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.2. GERMANY
  - 10.2.6.2.1. GERMANY ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.3. FRANCE
  - 10.2.6.3.1. FRANCE ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.4. ITALY
  - 10.2.6.4.1. ITALY ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.5. SPAIN
  - 10.2.6.5.1. SPAIN ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.6. SWITZERLAND
  - 10.2.6.6.1. SWITZERLAND ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.7. POLAND
  - 10.2.6.7.1. POLAND ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.2.6.8. REST OF EUROPE
  - 10.2.6.8.1. REST OF EUROPE ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
10.3. ASIA-PACIFIC
- 10.3.1. MARKET SIZE & ESTIMATES
- 10.3.2. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET DRIVERS
- 10.3.3. ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET CHALLENGES
- 10.3.4. ASIA-PACIFIC ARTIFICIAL VESSELS MARKET REGULATORY FRAMEWORK
- 10.3.5. KEY PLAYERS IN ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET
- 10.3.6. COUNTRY ANALYSIS
  - 10.3.6.1. CHINA
  - 10.3.6.1.1. CHINA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.2. JAPAN
  - 10.3.6.2.1. JAPAN ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.3. INDIA
  - 10.3.6.3.1. INDIA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.4. SOUTH KOREA
  - 10.3.6.4.1. SOUTH KOREA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.5. INDONESIA
  - 10.3.6.5.1. INDONESIA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.6. THAILAND
  - 10.3.6.6.1. THAILAND ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.7. VIETNAM
  - 10.3.6.7.1. VIETNAM ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.8. AUSTRALIA & NEW ZEALAND
  - 10.3.6.8.1. AUSTRALIA & NEW ZEALAND ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.3.6.9. REST OF ASIA-PACIFIC
  - 10.3.6.9.1. REST OF ASIA-PACIFIC ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
10.4. REST OF WORLD
- 10.4.1. MARKET SIZE & ESTIMATES
- 10.4.2. REST OF WORLD ARTIFICIAL BLOOD VESSELS MARKET DRIVERS
- 10.4.3. REST OF WORLD ARTIFICIAL BLOOD VESSELS MARKET CHALLENGES
- 10.4.4. REST OF WORLD ARTIFICIAL VESSELS MARKET REGULATORY FRAMEWORK
- 10.4.5. KEY PLAYERS IN REST OF WORLD ARTIFICIAL BLOOD VESSELS MARKET
- 10.4.6. REGIONAL ANALYSIS
  - 10.4.6.1. LATIN AMERICA
  - 10.4.6.1.1. LATIN AMERICA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES
  - 10.4.6.2. MIDDLE EAST & AFRICA
  - 10.4.6.2.1. MIDDLE EAST & AFRICA ARTIFICIAL BLOOD VESSELS MARKET SIZE & OPPORTUNITIES

11. COMPETITIVE LANDSCAPE

11.1. KEY STRATEGIC DEVELOPMENTS
- 11.1.1. MERGERS & ACQUISITIONS
- 11.1.2. PRODUCT LAUNCHES & DEVELOPMENTS
- 11.1.3. PARTNERSHIPS & AGREEMENTS
- 11.1.4. BUSINESS EXPANSIONS & DIVESTITURES
11.2. COMPANY PROFILES
- 11.2.1. B BRAUN MELSUNGEN AG
  - 11.2.1.1. COMPANY OVERVIEW
  - 11.2.1.2. PRODUCT LIST
  - 11.2.1.3. STRENGTHS & CHALLENGES
- 11.2.2. BECTON DICKINSON AND COMPANY
  - 11.2.2.1. COMPANY OVERVIEW
  - 11.2.2.2. PRODUCT LIST
  - 11.2.2.3. STRENGTHS & CHALLENGES
- 11.2.3. LEMAITRE VASCULAR INC
  - 11.2.3.1. COMPANY OVERVIEW
  - 11.2.3.2. PRODUCT LIST
  - 11.2.3.3. STRENGTHS & CHALLENGES
- 11.2.4. MEDTRONIC PLC
  - 11.2.4.1. COMPANY OVERVIEW
  - 11.2.4.2. PRODUCT LIST
  - 11.2.4.3. STRENGTHS & CHALLENGES
- 11.2.5. TERUMO MEDICAL CORPORATION
  - 11.2.5.1. COMPANY OVERVIEW
  - 11.2.5.2. PRODUCT LIST
  - 11.2.5.3. STRENGTHS & CHALLENGES
- 11.2.6. W L GORE AND ASSOCIATES
  - 11.2.6.1. COMPANY OVERVIEW
  - 11.2.6.2. PRODUCT LIST
  - 11.2.6.3. STRENGTHS & CHALLENGES
- 11.2.7. ARTIVION INC
  - 11.2.7.1. COMPANY OVERVIEW
  - 11.2.7.2. PRODUCT LIST
  - 11.2.7.3. STRENGTHS & CHALLENGES
- 11.2.8. GETINGE AB
  - 11.2.8.1. COMPANY OVERVIEW
  - 11.2.8.2. PRODUCT LIST
  - 11.2.8.3. STRENGTHS & CHALLENGES
- 11.2.9. MICROPORT SCIENTIFIC CORPORATION
  - 11.2.9.1. COMPANY OVERVIEW
  - 11.2.9.2. PRODUCT LIST
  - 11.2.9.3. STRENGTHS & CHALLENGES
- 11.2.10. JIANGSU BIODA LIFE SCIENCE CO LTD
  - 11.2.10.1. COMPANY OVERVIEW
  - 11.2.10.2. PRODUCT LIST
  - 11.2.10.3. STRENGTHS & CHALLENGES
- 11.2.11. ROUMAI MEDICAL
  - 11.2.11.1. COMPANY OVERVIEW
  - 11.2.11.2. PRODUCT LIST
  - 11.2.11.3. STRENGTHS & CHALLENGES
- 11.2.12. MEDICALEXPO
  - 11.2.12.1. COMPANY OVERVIEW
  - 11.2.12.2. PRODUCT LIST
  - 11.2.12.3. STRENGTHS & CHALLENGES
- 11.2.13. VASCULAR GRAFT SOLUTION
  - 11.2.13.1. COMPANY OVERVIEW
  - 11.2.13.2. PRODUCT LIST
  - 11.2.13.3. STRENGTHS & CHALLENGES